PSB-1737

• Description :

  PSB-1737 is a human-selective GPR17 agonist with an EC50 for human GPR17 of 270 nM, and its activity on murine GPR17 is relatively weak (EC50 > 10 μM) . PSB-1737 shows no significant inhibition at the glycine binding site of NMDA receptors, and has no significant agonistic or antagonistic activity on P2Y receptor subtypes. PSB-1737 can be used in demyelinating diseases (such as multiple sclerosis) or inflammatory-related anemia[1].

• UNSPSC :

  12352005

• Target :

  Orphan GPCR

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cardiovascular Disease

• Smiles :

  O=C(C1=C(CCC(O)=O)C2=C(C=C(C=C2)OC3=CC=CC=C3)N1)O

• Molecular Formula :

  C18H15NO5

• Molecular Weight :

  325.32

• References & Citations :

  [1]Baqi Y, et al. 3- (2-Carboxyethyl) indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17. J Med Chem. 2018 Sep 27;61 (18) :8136-8154.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [139896-80-3]